明輝國際(03828.HK)年度營收增15.3%至20.67億港元 末期息5港仙
格隆匯3月25日丨明輝國際(03828.HK)公佈年度業績,截至2023年12月31日止年度,收入增加15.3%至約20.67億港元;毛利上升18.1%至約5.02億港元;毛利率上升0.6個百分點至24.3%;公司擁有人應占溢利約1.04億港元(2022年度:約75.5百萬港元)。建議末期股息為每股5.0港仙。
截至2023年12月31日止年度,酒店供應品業務、營運用品及設備業務與健康護理及衞生用品業務的收入分別約16.97億港元、1.93億港元及1.77億港元,分別佔集團總收入的82.1%、9.4%及8.5%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.